Paclitaxel, a tubulin target, has been suggested to decrease the expression levels of Hsp27 and hence could be utilized to reduce the doxorubicin resistance in Hsp27 overexpressing tumor cells [83,84]. Here, HSPB1 is linked to neoplasm.